Umeclidinium/vilanterol combination inhaler efficacy and potential impact on current chronic obstructive pulmonary disease management guidelines

Bibliography

• Global initiative for chronic obstructive lung disease. 2014. Available from: www.goldcopd.com
   Google Scholar
• Tashkin DP, Celli B, Decramer M, et al. Bronchodilator responsiveness in patients with COPD. Eur Respir J 2008;31(4):742-50
   PubMed Web of Science ®Google Scholar
• D’Urzo AD, De Salvo MC, Ramirez-Rivera A, et al. In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium : a 3-week, randomized, double-blind, within-patient, multicenter study. Chest 2001;119(5):1347-56
   PubMed Web of Science ®Google Scholar
• Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007;146(8):545-55
   PubMed Web of Science ®Google Scholar
• Charles MS, Blanchette CM, Silver H, et al. Adherence to controller therapy for chronic obstructive pulmonary disease: a review. Curr Med Res Opin 2010;26(10):2421-9
   PubMed Web of Science ®Google Scholar
• Breekveldt-Postma NS, Koerselman J, Erkens JA, et al. Enhanced persistence with tiotropium compared with other respiratory drugs in COPD. Respir Med 2007;101(7):1398-405
   PubMed Web of Science ®Google Scholar
• Jones PW, Beeh KM, Chapman KR, et al. Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med 2014;189(3):250-5
   PubMed Web of Science ®Google Scholar
• Jones PW. St. George’s respiratory questionnaire: MCID. COPD 2005;2(1):75-9
   PubMedGoogle Scholar
• Cazzola M, Tashkin DP. Combination of formoterol and tiotropium in the treatment of COPD: effects on lung function. COPD 2009;6(5):404-15
   PubMedGoogle Scholar
• Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med 2013;1(3):199-209
   PubMed Web of Science ®Google Scholar
• Salmon M, Luttmann MA, Foley JJ, et al. Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases. J Pharmacol Exp Ther 2013;345(2):260-70
   PubMed Web of Science ®Google Scholar
• Cazzola M, Segreti A, Matera MG. New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol. Drug Des Devel Ther 2013;7:1201-8
   PubMed Web of Science ®Google Scholar
• Anoro Ellipta. [Medication guide and instructions for use]. 2014; Available from: www.thrxinc.com/pdf/ANORO_PI.pdf
   Google Scholar
• Slack RJ, Barrett VJ, Morrison VS, et al. In vitro pharmacological characterization of vilanterol, a novel long-acting beta2-adrenoceptor agonist with 24-hour duration of action. J Pharmacol Exp Ther 2013;344(1):218-30
   PubMed Web of Science ®Google Scholar
• Decramer M, Maltais F, Feldman G, et al. Bronchodilation of umeclidinium, a new long-acting muscarinic antagonist, in COPD patients. Respir Physiol Neurobiol 2013;185(2):393-9
   PubMed Web of Science ®Google Scholar
• Donohue JF, Anzueto A, Brooks J, et al. A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD. Respir Med 2012;106(7):970-9
   PubMed Web of Science ®Google Scholar
• Donohue JF, Kalberg C, Shah P, et al. Dose response of umeclidinium administered once or twice daily in patients with COPD: a pooled analysis of two randomized, double-blind, placebo-controlled studies. J Clin Pharmacol 2014;54(11):1214-20
   PubMed Web of Science ®Google Scholar
• Hanania NA, Feldman G, Zachgo W, et al. The efficacy and safety of the novel long-acting beta2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial. Chest 2012;142(1):119-27
   PubMed Web of Science ®Google Scholar
• Donohue JF, Maleki-Yazdi MR, Kilbride S, et al. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med 2013;107(10):1538-46
   PubMed Web of Science ®Google Scholar
• Lee TA, Pickard AS, Au DH, et al. Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease. Ann Intern Med 2008;149(6):380-90
   PubMed Web of Science ®Google Scholar
• Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Jama 2008;300(12):1439-50
   PubMed Web of Science ®Google Scholar
• Nelson HS, Weiss ST, Bleecker ER, et al. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006;129(1):15-26
   PubMed Web of Science ®Google Scholar
• Gershon A, Croxford R, Calzavara A, et al. Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease. JAMA Intern Med 2013;173(13):1175-85
   PubMed Web of Science ®Google Scholar
• Kew KM, Mavergames C, Walters JA. Long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2013;10:Cd010177
   PubMed Web of Science ®Google Scholar
• Goldenberg MM. Pharmaceutical approval update. P T 2014;39(2):112-18
   PubMedGoogle Scholar
• Decramer M, Anzueto A, Kerwin E, et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med 2014;2(6):472-86
   PubMed Web of Science ®Google Scholar
• Donohue JF, Niewoehner D, Brooks J, et al. Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study. Respir Res 2014;15(1):78
   PubMed Web of Science ®Google Scholar
• Feldman G. Safety and tolerability of the GSK573719/vilanterol combination in patients with COPD. Am J Respir Crit Care Med 2012;185(meeting abstracts):A2938
   Google Scholar
• Kelleher DL, Mehta RS, Jean-Francois BM, et al. Safety, tolerability, pharmacodynamics and pharmacokinetics of umeclidinium and vilanterol alone and in combination: a randomized crossover trial. PLoS One 2012;7(12):e50716
   PubMedGoogle Scholar
• Kelleher D, Tombs L, Preece A, et al. A randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects. Pulm Pharmacol Ther 2014;29(1):49-57
   PubMed Web of Science ®Google Scholar
• Nakahara N. Safety, tolerability and pharmacokinetics (pk) of single and repeat doses of Gsk573719 in healthy japanese subjects. Am J Respir Crit Care Med 2012;185(meeting abstracts):A2915
   Google Scholar
• Mathers CD, Loncar D. Projections of global mortality and burden of disease from. 2002 to 2030. PLoS Med 2006;3(11):e442
   PubMed Web of Science ®Google Scholar
• Lopez AD, Shibuya K, Rao C, et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J 2006;27(2):397-412
   PubMed Web of Science ®Google Scholar
• Celli B, Crater G, Kilbride S, et al. Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study. Chest 2014;145(5):981-91
   PubMed Web of Science ®Google Scholar